# TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

> **NCT03193853** · PHASE2 · COMPLETED · sponsor: **Joyce O'Shaughnessy** · enrollment: 12 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Tak-228 & Tak-117
- **DRUG:** Cisplatin & Nab Paclitaxel

## Key facts

- **NCT ID:** NCT03193853
- **Lead sponsor:** Joyce O'Shaughnessy
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-18
- **Primary completion:** 2020-03-17
- **Final completion:** 2022-12-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03193853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03193853, "TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03193853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*